Endocyte , Nasdaq: ECYT
Is developing EC145 (entering Phase III) for the treatment of ovarian cancer.
Industry: Health Care
First Day Return: +28.8%
| IPO Data | |
|---|---|
| IPO Date | 02/03/2011 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $75 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | West Lafayette, IN, United States |
| Founded | 1995 |
| Employees at IPO | 54 |
| Website www.endocyte.com | |
Endocyte (ECYT) Performance
